Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids

2 Oct 2021

Abstract excerpt

BACKGROUND: Patient-derived organoids (PDO) have been proposed as a novel in vitro method of drug screening for different types of cancer. However, to date, extrahepatic biliary tract carcinoma (eBTC) PDOs have not yet been fully established. METHODS: We collected six samples of gallbladder carcinoma (GBC) and one sample of extrahepatic cholangiocarcinoma (eCCA) from seven patients to attempt to establish eBTC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34600546
DOI: 10.1186/s12935-021-02219-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoidsPMID 34600546Read ↗

Establishment and Drug Screening of Patient-Derived Extrahepatic Biliary Tract Carcinoma OrganoidsSemantic proximity Read ↗

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical applicationSemantic proximity Read ↗

Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft.Semantic proximity Read ↗

The Origin of Patient-Derived Cancer Organoids from Pathologically Undiagnosed Specimen in Patients with Pancreatobiliary CancersSemantic proximity Read ↗

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screeningSemantic proximity Read ↗

Efficient Establishment of Bile-Derived Organoids From Biliary Cancer PatientsSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.Semantic proximity Read ↗

Application and mechanism of anticancer peptides in organoid models of intrahepatic cholangiocarcinomaSemantic proximity Read ↗

Patient-derived Tumor Xenograft and Organoid Models Established from Resected Pancreatic, Duodenal and Biliary CancersSemantic proximity Read ↗

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.Semantic proximity Read ↗

Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepositorySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.